AI-Powered Chemical Language Model Predicts Dual-Target Compounds for Drug Discovery

4 Sources

Researchers at the University of Bonn have developed an AI system that can predict chemical compounds capable of targeting two proteins simultaneously, potentially revolutionizing drug discovery for complex diseases like cancer.

News article

AI Revolutionizes Drug Discovery with Dual-Target Compound Prediction

Researchers at the University of Bonn have developed an innovative AI system that predicts chemical compounds capable of targeting two proteins simultaneously, potentially revolutionizing drug discovery for complex diseases like cancer 1234. This breakthrough, published in Cell Reports Physical Science, utilizes a chemical language model akin to ChatGPT, but specifically designed for molecular structures.

The Power of Dual-Target Compounds

In pharmaceutical research, compounds with multi-target activity are highly sought after due to their polypharmacology. Prof. Dr. Jürgen Bajorath, who heads the AI in Life Sciences area at the Lamarr Institute, explains, "Because compounds with desirable multi-target activity influence several intracellular processes and signaling pathways at the same time, they are often particularly effective - such as in the fight against cancer" 12.

While co-administration of different drugs can achieve similar effects, it often leads to unwanted drug-drug interactions and varying breakdown rates in the body. The ability to design a single compound with predefined dual effects could overcome these challenges.

Training the Chemical Language Model

The researchers trained their AI model using pairs of SMILES strings, which represent organic molecules and their structures as sequences of letters and symbols. Sanjana Srinivasan from Bajorath's research group elaborates, "One of the strings described a molecule that we know only acts against one target protein. The other represented a compound that, in addition to this protein, also influences a second target protein" 123.

The model was fed with over 70,000 of these pairs, allowing it to acquire implicit knowledge of how normal active compounds differed from those with dual effects. This training enabled the AI to suggest molecules that could act against multiple target proteins when given a compound targeting a single protein.

Fine-Tuning for Diverse Targets

To enhance the AI's capabilities, the researchers implemented a fine-tuning phase. This step prepared the model to suggest compounds that could influence different classes of enzymes or receptors, broadening its application in pharmaceutical research. After fine-tuning, the model successfully produced molecules known to act against desired combinations of target proteins 1234.

Implications for Drug Discovery

While the immediate creation of new compounds surpassing existing pharmaceuticals may not be the primary outcome, the true strength of this approach lies in its ability to generate novel ideas. Bajorath notes, "It is more interesting, from my point of view, that the AI often suggests chemical structures that most chemists would not even think of right away. To a certain extent, it triggers 'out of the box' ideas and comes up with original solutions that can lead to new design hypotheses and approaches" 1234.

This AI-driven approach to drug discovery opens up new possibilities for creating more effective medications with fewer side effects. By predicting dual-target compounds, it could significantly accelerate the development of treatments for complex diseases and potentially revolutionize the pharmaceutical industry.

Explore today's top stories

Goldman Sachs Pilots AI Coder Devin: A New Era of Hybrid Workforce on Wall Street

Goldman Sachs is testing Devin, an AI software engineer developed by Cognition, potentially deploying thousands of instances to augment its human workforce. This move signals a significant shift towards AI adoption in the financial sector.

TechCrunch logoCNBC logoQuartz logo

5 Sources

Technology

10 hrs ago

Goldman Sachs Pilots AI Coder Devin: A New Era of Hybrid

RealSense Spins Out from Intel, Secures $50 Million to Advance AI-Powered 3D Vision Technology

RealSense, Intel's depth-sensing camera technology division, has spun out as an independent company, securing $50 million in Series A funding to scale its 3D perception technology for robotics, AI, and computer vision applications.

TechCrunch logoTom's Hardware logoReuters logo

13 Sources

Technology

10 hrs ago

RealSense Spins Out from Intel, Secures $50 Million to

AI Adoption Accelerates: From Consumer Chatbots to Superintelligence Research

AI adoption is rapidly increasing across businesses and consumers, with tech giants already looking beyond AGI to superintelligence, suggesting the AI revolution may be further along than publicly known.

CNBC logoThe Motley Fool logo

2 Sources

Technology

18 hrs ago

AI Adoption Accelerates: From Consumer Chatbots to

Elon Musk's xAI Seeks Massive $200 Billion Valuation in Upcoming Funding Round

Elon Musk's artificial intelligence company xAI is preparing for a new funding round that could value the company at up to $200 billion, marking a significant increase from its previous valuation and positioning it as one of the world's most valuable private companies.

Bloomberg Business logoFinancial Times News logoMarket Screener logo

3 Sources

Business and Economy

10 hrs ago

Elon Musk's xAI Seeks Massive $200 Billion Valuation in

UN Report Calls for Stronger Measures to Combat AI-Driven Deepfakes

The United Nations' International Telecommunication Union urges companies to implement advanced tools for detecting and eliminating AI-generated misinformation and deepfakes to counter risks of election interference and financial fraud.

Reuters logoMarket Screener logo

2 Sources

Technology

10 hrs ago

UN Report Calls for Stronger Measures to Combat AI-Driven
TheOutpost.ai

Your Daily Dose of Curated AI News

Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.

© 2025 Triveous Technologies Private Limited
Instagram logo
LinkedIn logo